News

The Food and Drug Administration has placed a clinical hold on Gilead’s (GILD) HIV treatment trials of GS-1720 and/or GS-4182 ...
Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
Shares of Gilead Sciences, Inc. (GILD) traded over 1% lower on Tuesday noon after the company said that the U.S. Food and ...
Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...
Gilead Sciences has paused five clinical trials of its investigational HIV drugs GS-1720 and GS-4182 after the American medicines regulator raised safety concerns. The once-weekly oral regimen was ...
Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...
Gilead Sciences said the U.S. Food and Drug Administration has placed a clinical hold on studies of an investigational weekly HIV pill combination over signs of potentially weakened immune systems ...
The regulator ordered the company to pause its current trials of the pair, GS-1720 and GS-4182, after some participants were found to have low levels of CD4+ T-cells (a type of white blood cell).